Oxazepinoquinolinone BCL6 Inhibitors for Selective BTB Domain Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for agents that inhibit the tumorigenic effects of BCL6, a zinc finger transcription repressor involved in malignant B cell proliferation, by selectively binding to the BTB domain and preventing corepressor recruitment or inducing protein degradation.
Innovation Solution
Development of certain compounds, or their pharmaceutically acceptable salts, hydrates, or solvates, which act as BCL6 inhibitors, including (S)-10-((5-chloro-2-(3,3-difluoroazetidin-1-yl)pyrimidin-4-yl)amino)-2-cyclopropyl-3,3-difluoro-7-methyl-1,2,3,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-6(7H)-one and related derivatives, to inhibit BCL6 activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy agents are used to treat BCL6-driven cancers, then tumour growth may be inhibited, but selective inhibition of BCL6 activity is not achieved and harmful effects on normal cells occur
Solution Approach 1:
The patent applies local quality by designing compounds that specifically target the BTB domain of BCL6 protein with high selectivity. The compounds contain specific structural features (oxazepinoquinolinone core with substituted pyrimidinylamino groups) that enable selective binding to BCL6's BTB domain, distinguishing it from other proteins. This localized specificity ensures BCL6 inhibition without affecting other cellular processes, thereby reducing harmful effects on normal cells while maintaining reliable tumour growth inhibition.
2Reliability
If BCL6 inhibitors are developed to selectively bind BTB domain and prevent corepressor recruitment, then tumourigenic effects are inhibited, but complexity of compound structure increases
Solution Approach 1:
The patent applies segmentation by dividing the BCL6 protein target into its functional domains, specifically focusing on the BTB domain as the binding site. The compounds are designed with segmented structures where the oxazepinoquinolinone core provides the primary binding interaction with the BTB domain, while substituted pyrimidinylamino groups extend to prevent corepressor recruitment. This segmented approach allows selective inhibition of tumourigenic effects through targeted domain interaction without requiring complete structural coverage of the entire BCL6 protein.
Solution Approach 2:
The patent employs an intermediary mechanism where the designed compounds act as mediators between the BTB domain and corepressor proteins. The compounds contain specific structural elements (substituted pyrimidinylamino groups attached to oxazepinoquinolinone core) that facilitate binding to the BTB domain while sterically or electrostatically blocking corepressor recruitment. This intermediary approach enables selective inhibition of tumourigenic effects by interrupting the BCL6-corepressor interaction without requiring direct binding to multiple domains, thereby managing structural complexity.
3Reliability
If new BCL6 inhibitor compounds are synthesized with specific structural features, then selectivity and efficacy are improved, but difficulty of manufacture increases
Solution Approach 1:
The patent applies preliminary action by pre-organizing the molecular structure of the compounds to favor the active conformation required for BCL6 binding. The oxazepinoquinolinone core structure is designed with rigidified elements and pre-positioned substituted pyrimidinylamino groups that are already oriented to interact with the BTB domain. This preliminary structural arrangement reduces the need for complex post-synthesis modifications and facilitates more straightforward manufacturing while maintaining high selectivity and efficacy.
Data Source
AI summary
The present invention relates to compounds that function as inhibitors of BCL6 (B-cell lymphoma 6) activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.